MarketPulse

Anktiva

6 articles
The Motley FoolThe Motley Fool··James Brumley

ImmunityBio Surges 11% on First Asian Approval for Bladder Cancer Drug

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.
IBRXAsia-Pacific expansionbladder cancer
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for Anktiva

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.
IBRXbladder cancerAnktiva
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges 10% on NK Cell Therapy Manufacturing Milestone

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.
IBRXBBPclinical trialbladder cancer
BenzingaBenzinga··Vandana Singh

ImmunityBio Surpasses Enrollment Target in Pivotal Cancer Study as Anktiva Sales Accelerate

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.
IBRXFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

ImmunityBio Expands European Presence With 85-Person Sales Team for Bladder Cancer Drug

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.
IBRXEuropean expansionbladder cancer
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer